ReviewJournal of thoracic disease2026
Transbronchial cryobiopsy for peripheral pulmonary lesions using ultrathin bronchoscopy: a narrative review.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transbronchial Access of Solitary Pulmonary Nodules Without Bronchus Sign Using a Novel Puncture Dilatation Catheter: Initial Feasibility Experience.Respirology case reports · 2026Article
- Feasibility of direct cryobiopsy specimen retrieval through the working channel of an ultrathin bronchoscope-a retrospective study of single institute.Journal of thoracic disease · 2026Article
- Diagnostic Yield and Safety of Radial Probe Endobronchial Ultrasound-Guided Transbronchial Lung Cryobiopsy with a Guide Sheath in Pulmonary Lesions < 3 cm.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: With the rising detection of peripheral pulmonary lesions (PPLs) and ground-glass opacities (GGOs) owing to widespread lung cancer screening, obtaining high-quality tissue for next-generation sequencing (NGS) has become critical. Conventional forceps biopsy often yields insufficient samples with crush artefacts, whereas ultrathin bronchoscopy (UTB) provides access to the peripheral airways. This narrative review aimed to evaluate the current evidence on the diagnostic utility, safety, and specimen quality of transbronchial cryobiopsy (TBLC) using a 1.1-mm cryoprobe in conjunction with UTB. Methods: We conducted a comprehensive literature search for articles published between January 1, 2019 and October 31, 2025 using PubMed. We prioritized prospective and retrospective studies as well as case series investigating the clinical utility and safety of the 1.1-mm cryoprobe for PPLs. Single case reports were excluded. Key Content and Findings: The 1.1-mm cryoprobe exhibited superior flexibility, allowing access to the distal airways without compromising UTB performance. When integrated with advanced guidance technologies, such as radial endobronchial ultrasound (rEBUS), cone-beam computed tomography (CBCT), and robot-assisted bronchoscopy, cryobiopsy attained superior diagnostic yields compared with forceps biopsy. This advantage was particularly pronounced for GGO-predominant lesions and lesions identified as "adjacent to" on rEBUS, where forceps biopsy frequently fails. Crucially, cryobiopsy retrieved large, crush-free, Conclusions: UTB-guided cryobiopsy represents a paradigm shift in diagnostic bronchoscopy, successfully balancing high diagnostic performance with acceptable safety. Overcoming the limitations of conventional sampling is essential in the era of precision medicine. Ongoing multicenter randomized controlled trials (RCTs) are expected to further cement the position of UTB-guided cryobiopsy as a standard-of-care modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.